Himalaya Nutravedics India Limited
SMEBSE
Issue details
Price band
₹100 - ₹106
Lot size
1,200 shares
Issue size
₹26 Cr
Min. investment
₹1,27,200
Registrar
KFin Technologies
Subscription
2.24x · 1,033 applications
Grey market premium
₹0 · 0%
Save your family's PANs once and check allotment for everyone the moment results are out.
Sign in with a mobile OTP. It takes 20 seconds.
IPO Timeline
Open
22 Sep
Close
24 Sep
Allotment
25 Sep
Listing
29 Sep
- Refunds & demat credit
- 26 Sep 2026
- Mandate end
- 9 Oct 2026
We calculate these dates from the allotment and close dates, so please treat them as indicative.
Application size
| Category | Minimum | Maximum |
|---|---|---|
| Retail | 1,200shares 1 lot · ₹1,27,200 | 1,200shares 1 lot · ₹1,27,200 |
| HNI | 2,400shares 2 lots · ₹2,54,400 | No limit funds permitting |
Based on the upper price band of ₹106 and a lot of 1,200 shares.
Subscription
| Quota | Shares offered | Shares bid | Applications | Subscribed |
|---|---|---|---|---|
| NII | 4,82,400 | 14,00,400 | 143 | 2.90x |
| Retail (IND) | 8,32,800 | 21,33,600 | 889 | 2.56x |
| Total | 17,89,200 | 40,08,000 | 1,033 | 2.24x |
Last updated 38 days ago.
Issue structure
Face value
₹10 per share
Issue type
Bookbuilding IPO
Sale type
Fresh capital only
Fresh issue
₹25 Cr
23,73,600 shares
Shares pre-issue
63,06,720
Shares post-issue
88,06,320
Valuation & ratios
| Metric | Pre-IPO | Post-IPO |
|---|---|---|
| EPS | 11.72 | 8.39 |
| P/E | 9.04 | 12.63 |
| Market cap | ₹66.85 Cr. | ₹93.35 Cr |
| KPI | Mar 31, 2026 |
|---|---|
| ROE | 63.87% |
| ROCE | 36.41% |
| Debt/Equity | 0.31 |
| RoNW | 45.12% |
| PAT Margin | 17.16% |
| EBITDA Margin | 18.82% |
| NAV | 26.70 |
| Price to Book Value | 3.97 |
Financials
| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total income | 43.12 | 21 | 14.43 |
| Profit after tax | 7.39 | 2.23 | 0.43 |
| EBITDA | 8.1 | 2.99 | 0.94 |
| Net worth | 16.38 | 6.75 | 1.34 |
| Assets | 24.42 | 10.82 | 6.09 |
| Reserves & surplus | 10.07 | 2.76 | 0.53 |
| Total borrowing | 5.13 | 1.76 | 3.24 |
Figures in ₹ crore, as reported by the company in its offer document.
Objects of the issue
- 1.Funding Working Capital Requirements₹13.75 Cr
- 2.Business Development and Digital Marketing Activities₹7.5 Cr
- 3.General Corporate Purposes—
What the company says it intends to do with the money raised.
Recent comparable IPOs
| Company | Issue price | P/E | Listing close | Listing gain |
|---|---|---|---|---|
| Bio Medica Laboratories Ltd.SME | ₹139 | 13.03 | ₹115.80 | -16.69% |
| Goldline Pharmaceutical Ltd.SME | ₹43 | 10.47 | ₹56.77 | +32.02% |
| Speciality Medicines Ltd.SME | ₹124 | 9.27 | ₹125.90 | +1.53% |
| Accretion Nutraveda Ltd.SME | ₹129 | 26.27 | ₹191.20 | +48.22% |
| KRM Ayurveda Ltd.SME | ₹135 | 17.32 | ₹180.70 | +33.85% |
| Curis Lifesciences Ltd.SME | ₹128 | 12.44 | ₹141.00 | +10.16% |
| Aptus Pharma Ltd.SME | ₹70 | 11.29 | ₹84.84 | +21.20% |
| Symbiotec Pharmalab Ltd.Mainboard | ₹988 | 55.44 | ₹1,097.70 | +11.10% |
| Hexagon Nutrition Ltd.Mainboard | ₹45 | 22.69 | ₹53.19 | +18.20% |
| Sai Parenteral's Ltd.Mainboard | ₹392 | 72.19 | ₹405.70 | +3.49% |
| Corona Remedies Ltd.Mainboard | ₹1062 | 43.47 | ₹1,438.40 | +35.44% |
| Rubicon Research Ltd.Mainboard | ₹485 | 55.75 | ₹628.20 | +29.53% |
Past listing performance of comparable issues. This is not a forecast: listing gains vary widely and can turn negative.
Issue fundamentals compiled from the company's offer document via Chittorgarh, last read 27 Sep 2026. Always verify against the RHP before applying.